TVRD today
$1.18+$0.02 (+2.16%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bullish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $1.42
Key levels
Resistance$1.61
Resistance$1.42
Support$0.93
Support$0.77
Latest news & SEC filings
EarningsTvardi Therapeutics Reports Third Quarter 2026 Financial Results
EarningsTvardi Therapeutics posts smaller Q3 loss than analysts expected
SEC FilingTvardi Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All TVRD news →About Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule drugs that block STAT3, a signaling protein involved in inflammation and abnormal cell growth. Its lead candidate, TTI-101, is being tested in patients with liver cancer, while a second candidate, TTI-109, is in early-stage testing. The company focuses on diseases where STAT3 signaling is dysregulated.
Based on the company's 10-K filed Mar 31, 2026.
Nasdaq · Healthcare
Tvardi Therapeutics, Inc. (TVRD)
What Is the Price Target for TVRD?
SEPT Low Target
$3.00
SEPT Mid Target
$8.00
SEPT High Target
$10.00
Analyst Consensus
$8.00
Is TVRD a Buy or Sell Right Now?
Thesis
- •Revenue growing -66.0% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TVRD.
Start Free Trial →Is TVRD Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$8.00
7
Moat Score
NONE
2/9
Piotroski Score
-6.2
Altman Z-Score
What Is Smart Money Doing with TVRD?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TVRD Growth Story
Revenue YoY
-66.0%
3yr Revenue CAGR
-32.3%
EPS Growth YoY
71.45%
FCF Growth YoY
N/A%
Revenue Trend
DECLINING
Dark Pool Trades for TVRD
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TVRD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:34:05 | $1.11 | 1,000 | $$1K | SELL |
| 20:27:06 | $1.09 | 8,600 | $$9K | SELL |
| 20:00:50 | $1.12 | 1,000 | $$1K | BUY |
| 18:26:08 | $1.10 | 6,868 | $$8K | SELL |
| 18:26:08 | $1.10 | 3,278 | $$4K | SELL |
5 dark pool trades shown · $$23K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Tvardi Therapeutics, Inc. (TVRD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TVRD — frequently asked questions
What is TVRD stock price today?
Tvardi Therapeutics, Inc. (TVRD) is at $1.18, up 2.16% (+$0.02) at the Nov 13, 2026 close.
Why is TVRD stock moving today?
Latest TVRD news — Nov 13, 2026: Tvardi Therapeutics Reports Third Quarter 2026 Financial Results · Nov 13, 2026: Tvardi Therapeutics posts smaller Q3 loss than analysts expected
What is the TVRD price target?
The average analyst price target for TVRD is $8.00, ranging from $3 to $10, based on 8 analysts. Latest: Chardan upgrade on Oct 20, 2026.
What do analysts rate TVRD?
Analyst ratings for TVRD: 2 Buy, 5 Hold, 1 Sell — consensus Hold.
Did TVRD beat earnings?
TVRD last reported on Aug 14, 2026: EPS -$0.69 vs -$0.70 expected — a beat of 2.0%.
What is TVRD's P/E ratio?
TVRD trades at a P/E of 28.9 vs a Healthcare average of 17.4.
Does TVRD pay a dividend?
TVRD does not currently pay a dividend.
What are TVRD support and resistance levels?
Support: $0.93, $0.77. Resistance: $1.42, $1.61, $1.96.
What are insiders doing with TVRD?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on TVRD?
Nov 13, 2026: Tvardi Therapeutics Reports Third Quarter 2026 Financial Results · Nov 13, 2026: Tvardi Therapeutics posts smaller Q3 loss than analysts expected · Nov 13, 2026: Tvardi Therapeutics, Inc. filed a report on a major company event (Form 8-K)